Journal
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
Volume 25, Issue 11, Pages 1726-1731Publisher
WILEY
DOI: 10.1111/j.1440-1746.2010.06437.x
Keywords
cirrhosis; disease progression; fatty liver; Fibroscan; hepatitis B; hepatitis C; liver fibrosis; transient elastography
Categories
Ask authors/readers for more resources
In clinical practice, it is important to assess the severity of liver fibrosis in patients with various liver diseases to determine the prognosis, decide treatment, and monitor disease progression and response to treatment. Liver biopsy is limited by its invasiveness and patient acceptability. The development of transient elastography provides clinicians with a non-invasive, accurate, and reproducible tool to estimate liver fibrosis. The technique has been validated among many liver diseases and requires only simple training. Due to its non-invasive nature and ease of use, transient elastography can be used repeatedly on patients, and is optimal for large-scale epidemiological studies, in which stable patients with no indication for liver biopsy can also be included. However, falsely-high liver stiffness measurements might occur during acute hepatitis, extrahepatic cholestasis, congestive heart failure, and amyloidosis. Failed acquisition is also common in obese patients. The development of S and XL probes might cater for different population groups, but calibration in patients with liver biopsy is essential.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available